GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Leukemia & Lymphoma, Informa UK Limited, Vol. 54, No. 1 ( 2013-01), p. 181-183
    Type of Medium: Online Resource
    ISSN: 1042-8194 , 1029-2403
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2013
    detail.hit.zdb_id: 2030637-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Case Reports in Hematology, Hindawi Limited, Vol. 2013 ( 2013), p. 1-3
    Abstract: High-output cardiac failure in multiple myeloma (MM) is related to arteriovenous shunting in bone infiltrate disease. We describe such a complication in a patient with primary plasma cell leukemia (pPCL) without bone disease. We review the mechanisms that could be involved. As previously described, traditional cardiac failure therapy is not effective. pPCL therapy should not be delayed.
    Type of Medium: Online Resource
    ISSN: 2090-6560 , 2090-6579
    Language: English
    Publisher: Hindawi Limited
    Publication Date: 2013
    detail.hit.zdb_id: 2627639-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Wiley ; 2014
    In:  Journal of the International AIDS Society Vol. 17, No. 4S3 ( 2014-11)
    In: Journal of the International AIDS Society, Wiley, Vol. 17, No. 4S3 ( 2014-11)
    Abstract: In non‐HIV patients, Monoclonal Gammopathy of Undetermined Significance (MGUS) is associated with an increased risk of subsequent development of haematologic malignancies, especially multiple myeloma (MM) and it has been recently demonstrated that MM is always preceded by a MGUS phase. A higher prevalence of MGUS and MM has been observed in HIV patients compared to the general population. Nevertheless, it has been shown that MGUS in the context of HIV can disappear with antiretroviral therapy (ART). So, measuring MGUS prevalence in HIV patients in the recent period appears of special interest. Materials and Methods From January to June 2014, in each out‐patient seen in our unit, a serum protein electrophoresis was performed. Results A total of 393 patients were screened. Eight patients with HIV2 and one patient with HIV1+HIV2 infection were excluded. Finally, 383 patients (173 female, 210 male) with HIV1 infection were analyzed. Characteristics of patients were as follows: median age 42.2 years (19.1–79.1), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) co‐infection 47 (18.8%), median CD4 610 (2–1758), CD8 793 (113–4010), presence of a past AIDS event for 88 patients (23%). Median time with HIV infection was 11 years (0–30). Three hundred fifty‐nine patients (93.7%) were on ART for a median duration of 105 months (0–287). For 320 patients (83.6%), viral load was below 50 viral copies/ml. Twelve cases of MGUS (3.1%) were observed: IgG Kappa (five cases), IgG Lambda (five cases), biclonal with two IgG Kappa (one case) and in one case, three monoclonal immunoglobulins were observed (IgG Kappa×2+IgG Lambda). The monoclonal immunoglobulin's level was low and below 1 g/l in all cases except two (2.1 and 11.6 g/l). No factor was found to be predictive of the presence of MGUS in particular age, CD4, HBV/HCV co‐infection, viral load or ART. Conclusions In the context of modern ART, the prevalence of MGUS remains above those observed in the general population. Even if the level of monoclonal spike observed in our cohort is generally low, an excess risk of subsequent development of MM could be present. Nevertheless, a prospective follow‐up of HIV patients with MGUS is necessary to determine this risk.
    Type of Medium: Online Resource
    ISSN: 1758-2652 , 1758-2652
    Language: English
    Publisher: Wiley
    Publication Date: 2014
    detail.hit.zdb_id: 2467110-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 2754-2754
    Abstract: Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen is widely used for the treatment of B-cell malignancies and others auto immune pathologies. HBV reactivation is a well known life-threatening complication of rituximab. In 2004, US FDA recommended HBV screening of high risk patients before the first Rituximab infusion and treatment of patients with positive hepatitis B surface antigen or antibody to hepatitis B core. Then in 2008, CDC recommended screening of all patients. EASL in 2012 recommended treating patients with positive HBsAg or anti-HBc. The aim of this study was to evaluate HBV screening and management before the initiation of rituximab. We conducted a retrospective monocentric study in Argenteuil Hospital, located in the neighborhood of Paris, France. All patients who received rituximab between January 1, 2008 and December 31, 2013 were included. The list was exhaustive through the Pharmacy Informatics. Laboratory Informatics gave test dates and results for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antibody (anti-HBc) and antibody to hepatitis B surface (anti-HBs). We investigated for medical record when serology was missing. We considered serology as not done when no result was found. The data are described as number and percentages for categorical variables and mean ± standard deviation or median for continuous variables. Between-group comparisons were done using the chi-square test for categorical data and Student t-test for continuous data. P values 〈 0.05 were considered statistically significant. Statistical analysis was performed with R software (http://cran-project.org). We included 509 patients with a mean age of 65.5 when rituximab treatment was initiated. Men represented 58% and 33% of patients were born outside of France, mainly in Africa or in Asia. Rituximab was mainly used in cancer treatment (91%) and chemotherapy was associated in 82% of cases. Five medical records were lost, so the study was conducted for 504 patients. The rate of assessment for HBV serology was 79.4% (104 not done among the 504). Sex, country of origin, indication for treatment or cancer were not statistically significant for the quality of screening. No difference was found depending on the period. A trend in favor a worst screening for older patients was seen: median age for screening patients was 64.8 versus 68.1 (p=0.053). Among the 9 patients who were HBsAg+, 8 received analogue nucleoside and did not reactivate HBV. These patients have also been screened for Hepatitis Delta virus. The patient who did not receive a preemptive therapy reactivated HBV. This patient was initially treated in another center without HBV screening. When he was referred to us an important hepatic flare secondary to HBV reactivation was found. Six among the 11 patients who were anti-HBc+ /antiHBs- received preemptive therapy and no reactivation was seen. Adenofovir then tenofovir was chosen preferentially. None of the patients with anti-HBc and anti-HBs received preemptive antiviral therapy as recommended since 2004. Among them, one patient treated with rituximab and chlorambucil for CLL reactivated HBV. Evolution was favorable on entecavir. To summarize, our HBV management before Rituximab first infusion must be improved. All patients with HBc with or without HBs antibody are of risk of HBV reactivation. Pre-emptive treatment should be proposed to all patients with HBc positive antibody. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Hindawi Limited ; 2012
    In:  Case Reports in Hematology Vol. 2012 ( 2012), p. 1-3
    In: Case Reports in Hematology, Hindawi Limited, Vol. 2012 ( 2012), p. 1-3
    Abstract: Cases of anaplastic large-cell lymphoma (ALCL) of T phenotype are sparse in the setting of HIV patients. We report herein a case of T-ALCL, with an advanced stage, pulmonary involvement, high HIV viral load, and low CD4 level. Anaplastic lymphoma kinase (ALK) protein expression was negative. Anthracyclin-based chemotherapy was unsuccessful. The literature review was performed focusing on incidence, clinical characteristics, prognosis, and physiopathology of ALCL in HIV patients. More data are needed to improve the knowledge of such cases and to define a better treatment approach.
    Type of Medium: Online Resource
    ISSN: 2090-6560 , 2090-6579
    Language: English
    Publisher: Hindawi Limited
    Publication Date: 2012
    detail.hit.zdb_id: 2627639-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...